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ABSTRACT 
 
Background: Several studies showed that urinary concentration of neutrophil gelatinase-associated lipocalin (NGAL) increased 
in patients with chronic heart failure and mildly reduced glomerular filtration rate (GFR). Objective: To compare the NGAL 
levels between patients with high N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and those with low NT-proBNP 
levels. Methods: In this case control study, we estimated the GFR, NT-proBNP, NGAL and fibroblast growth factor 23 (FGF- 
23) levels in twenty peritoneal dialysis patients, along with twenty age- and sex-matched healthy controls. Therefore, in patients 
with NT-proBNP levels higher than 1000 pg/mL (hypervolemic patients) and in patients with NT-proBNP lower than 1000 
pg/mL (normovolemic patients), serum NGAL and parameters of echocardiography were evaluated at the beginning of the study 
and again after three months. Results: In this study, patients’ serum NT-proBNP levels, NGAL and FGF23 were significantly 
higher than in the healthy control group (p <0.05). There were no significant differences between hypervolemic patients and 
normovolemic patients with regard to age, sex, body mass index, serum creatinine, parathyroid hormone, blood urea nitrogen 
(BUN), urine volume, GFR and left ventricular end-diastolic diameter, left atrial diameter or aortic root size measured by 
echocardiographic evaluation at the beginning and at the second measurement (p >0.05). Plasma NT-proBNP levels were 
markedly greater in hypervolemic patients (13323.3±11235.9 pg/mL) than those of normovolemic patients (456.1±266.7 pg/mL) 
(p <0.05). In hypervolemic patients, there was a significant decrease in NT-proBNP levels at the second measurement (from 
13323.3±11235.9 pg/mL to 9667.3±9483.2 pg/mL) (p <0.05). However, no significant changes were detected in serum NGAL 
levels, FGF23 or GFR. In normovolemic patients, serum NT-proBNP, NGAL, FGF23 and GFR did not change (p >0.05). 
Conclusion: Serum NT-proBNP, NGAL and FGF23 levels are significantly higher in dialysis patients. This further indicates the 
need for a more comprehensive study of hypervolemia and the reduction of NGAL and residual renal function, which we often 
encounter in patients with renal insufficiency. 
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eutrophil gelatinase-associated lipocalin (NGAL) 
is a member of the lipocalin family of proteins, 
and it is secreted from kidney tubule cells at low 
concentrations. Many studies have shown that NGAL is 
produced in the kidneys after ischemic or nephrotoxic 
damage [1–4]. The risk of cardiovascular morbidity and 
mortality in patients with chronic renal failure (CRF) is 
much higher than in the general population [5–7]. High 
levels of fibroblast growth factor 23 (FGF23) plays an 
important role in independent pathophysiological 
mechanisms among cardiovascular disease risk factors in 
 
 
chronic kidney disease [8–10]. Epidemiologic studies 
suggest that elevation of FGF23 is strongly associated with 
left ventricular hypertrophy (LVH) and that high FGF23 is 
an independent risk factor for congestive heart failure 
(CHF) and mortality [11, 12]. 
 
FGF23 is a phosphatonin that regulates phosphate 
levels in the intestine, bone and kidneys. Previous studies 
have shown that FGF23 elevation is associated with LVH 
in patients with CRF who do not undergo dialysis. 
Increased FGF23 concentrations in hemodialysis patients 
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have been linked to increased mortality in the first year of 
dialysis treatment [13]. Studies in the general population 
have shown that brain natriuretic peptide (BNP) is a more 
potent marker of LVH and systolic dysfunction than other 
peptides [14]. Mallamaci and colleagues have shown that 
cardiac natriuretic peptides (especially BNP) are sensitive 
molecules in the diagnosis of LVH and systolic 
dysfunction in dialysis patients [15]. 
 
MATERIALS & METHODS 
 
After obtaining ethical committee approval and consent 
from the parents, we included 20 patients, who underwent 
peritoneal dialysis in the peritoneal dialysis unit of a 
medical university, Turkey. Exclusion criteria were as 
follows: patients who were younger than 18 years of age, 
who had cancer, who had experienced physical trauma 
within the last month, who had undergone a coronary 
bypass, who had a surgical operation or burn history who 
exhibited the presence of acute infection, whose daily 
urine output was <300mL or who had a history of 
symptomatic or decompensated liver disease, myocardial 
infarction, peripheral artery disease or cerebrovascular 
disease. 
 
Patients were evaluated for age, gender, height, weight, 
body mass index (BMI), daily urine output, CRF duration, 
etiology, glomerular filtration rate (GFR) values, 
hemogram, serum creatinine, blood urea nitrogen (BUN), 
calcium, phosphorus, albumin and parathormone levels. 
This assessment was made at the beginning and end of the 
study i.e. at an interval of three-months. Blood samples 
were taken for FGF23, NGAL and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) in patients two times in 
the beginning and the third month of follow-up. 
Transthoracic echocardiography was performed two times 
by the same cardiologist at the beginning and end of the 
follow-up period. 
 
Twenty healthy individuals with no known active 
diseases were selected as a control group in the same age 
range as the patients and in them, FGF23, NGAL, NT- 
proBNP and fetuin levels were studied. Heparinized 
plasma was used in the study, and the collected blood was 
stored at -70 °C before the study. At the beginning of the 
study, the samples were allowed to stand at room 
temperature for dissolution. Lipocalin-2/NGAL was 
studied with the ELISA method on a Brio-brand Seac 
SRL-model device (BioVendor GmbH, D-69120 
Heidelberg, Germany) with the BioVendor-brand kit (Brio, 
Seac SRL, Radim Company, Calenzano, Firenze, Italy). 
Before starting to work, the lyophilized stock in the kit  
was dissolved in a standard dilution buffer at a 
concentration of 10 ng/mL. Serial dilutions were 
performed at concentrations of 5 ng/mL, 2.5 ng/mL, 1.25 
ng/mL, 0.6 ng/mL and 0.3 ng/mL. 
Plasma samples stored at -70 °C were thawed at room 
temperature and diluted 30-fold with the dilution buffer. 
Diluted 100 μL was taken from the samples and pipetted 
into 96 plate-coated wells with a lipocalin-2/NGAL 
antibody. Each well was washed three times with 350 μL 
of wash solution after incubation for one hour at the plate 
room temperature. After washing, 100 μL of Streptavidin- 
HRP solution was pipetted into each of the plates, and then 
the plate surface was sealed and incubated for 30 minutes 
at room temperature. In addition, 100 μL of stabilized 
chromogen (substrate) was added to the plate following the 
washing step. The plate incubation was carried out in the 
dark at room temperature for 10 minutes. A stop solution 
containing 100 μL H2SO4 was added to the plates, and the 
reaction was stopped. At the end of the study, the optical 
density (OD) in the plates was evaluated in an ELISA 
reader (ELX800, BIO-TEK Instruments) at a wavelength 
of 450 nm and the results were calculated in ng/mL. 
 
FGF23 assay was performed by ELISA method (Brio, 
Seac SRL, Radim Company, Calenzano, Firenze, Italy). A 
Millipore kit was used (Millipore Corporation, Billerica, 
MA, USA), working on a Brio Seac SRL-model device. 
Before starting to work, the lyophilized stock in the kit  
was dissolved in 0.5 mL of deionized water at a 
concentration of 7200 pg/mL. Standards were prepared at 
2400 pg/mL, 800 pg/mL, 266 pg/mL, 88pg/mL, 29 pg/mL 
and 9 pg/mL concentrations by serial dilution with an 
assay running buffer. After adjusting the wells for blank, 
standard, control and samples, 50 μL of the matrix solution 
was pipetted into these wells. Again, blank and sample 
wells were pipetted into 50 μL wells from the assay 
running buffer. Samples were taken 50 μL from the 
standard and controls and pipetted into wells that were 
previously detected. After incubation for two hours at plate 
temperature, each well was washed three times with 300 
μL of wash solution. Then 100 μL of detection antibody 
solution was added to all wells, and the surface of the plate 
was closed. After incubation for one hour at the plate room 
temperature, each well was washed three times with 300 
μL of wash solution. Subsequently, 100 μL of enzyme 
solution was pipetted into each cassette, and the plate 
surface was sealed and incubated for 30 minutes at room 
temperature. Each well was washed three times with 300 
μL of wash solution, and 100 μL of stabilized chromogen 
(substrate) was added to the plate. After incubation of the 
plate in the dark at room temperature for 20 minutes, stop 
solution containing 100 μL H2SO4 was added to the plate 
and the reaction was stopped. At the end of the study, the 
OD in the plates was evaluated in an ELISA reader 
(ELX800, BIO-TEK Instruments) at a wavelength of 450 
nm. Results are given in pg/mL. 
 
The NT-proBNP was run on a Siemens-branded 
Immulite 2000 device using the chemiluminescence 
method (Siemens Healthcare Diagnostics Products Ltd., 
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Llanberis, Gwynedd LL55 4 EL, United Kingdom). The 
results of the work performed on the fully automated 
device that has been checked and calibrated are given in 
pg/mL. 
 
Statistical analysis was as follows: the square sample t- 
test was used for comparison of normal-range measures. 
The Mann-Whitney U-test was used for comparison of 
non-normalized measurements, and p < 0.05 was 
considered statistically significant. Wilcoxon signed rank 
tests and paired t-tests were used according to their 
distributions for comparison of recurrent measurements. 
Spearman correlation analysis was performed. Multivariate 
regression analysis was used to find determinants of serum 
NGAL levels. 
 
RESULTS 
 
There were 12 males and 8 females in both the group i.e. 
patient and control group. No significant difference was 
found between the patient and control groups in terms of 
gender and age (p >0.05). A statistically significant 
difference was found between GFR, modification of diet in 
renal disease (MDRD), BUN, creatinine, proBNP, NGAL 
and FGF23 levels between the patient and control groups 
(p <0.05). The GFR and MDRD were higher in the control 
group while BUN, creatinine, proBNP, NGAL and FGF23 
levels were higher in the patient group (Table 1). 
 
In the patient group, there was no significant difference 
in terms of sex, age, GFR, MDRD, calcium, phosphorus or 
BMI between patients with proBNP >1000 and proBNP 
<1000 (p >0.05). Among the two groups, albumin was 
significantly different between the first and second 
evaluation of proBNP and these two evaluations (p <0.05). 
Albumin was lower in the loaded group with proBNP > 
1000 pg/mL (Table 2). 
 
Between the two groups, there was no significant 
difference in BUN, creatinine, parathormone, proBNP, 
NGAL, FGF23, LVEDD measurement, left atrium 
diameter measurement, aortic root measurement and 
residual urine volume, at first and second evaluation (p 
>0.05). There was no statistically significant difference 
between two groups of first and second NGAL, FGF23 
and MDRD measurements (p >0.05). 
 
In the evaluation of patients with a proBNP level 
<1000 pg/mL, BUN, creatinine, parathormone, MDRD, 
proBNP, NGAL, FGF23, LVEDD and left atrial diameter 
were  found  to  be  significant  in  terms  of  two  values (p 
>0.05). The difference between the two measurements of 
the aortic root diameter and residual urine in initial 
evaluation of patients with a proBNP <1000 pg/mL was 
statistically significant (p <0.05). In patients with a 
proBNP  <1000 pg/mL, aortic root diameter  was  higher in 
the first measurement, while residual urine was higher in 
the second measurement (Table 3). 
 
Table 1: Comparison of initial assessment of patient 
and control group 
 
Parameters 
Tested 
Patient 
group, n: 20 
(Mean ± SD) 
Control 
group, n: 20 
(Mean ± SD) 
p-value 
Gender 
(female) n (%) 
9 (45%) 8 (40%) 0.500 
Age (year) 44.8 ± 15.9 35.3 ± 4.8 0.063 
GFR (mL/min.) 12.50 ± 5.5 130.6 ± 31.5 0.000 
MDRD 
(mL/min.) 
8.5 ± 4.1 97.8 ± 30.0 0.000 
BUN (mg/dL) 55.4 ± 20.9 12.0 ± 2.5 0.000 
Creatinine 
(mg/dL) 
7.5 ± 2.8 0.8 ± 0.2 0.000 
proBNP 
(pg/mL) 
6839.4 ± 
10168.4 
46.7 ± 23.0 0.000 
NGAL (ng/mL) 186.7 ± 51.2 83.1 ± 29.1 0.000 
FGF23 
(pg/mL) 
455.9 ± 621.7 20.8 ± 16.7 0.000 
 
GFR: glomerular filtration rate; MDRD: Modification of 
Diet in Renal Disease; BUN: blood urea  nitrogen; 
proBNP: N-terminal pro-brain natriuretic peptide; NGAL: 
neutrophil gelatinase-associated lipocalin; FGF23: 
fibroblast growth factor 23. 
 
The difference between the two measurements  of 
BUN, proBNP and aortic root diameter in the initial 
evaluations of patients with proBNP >1000 pg/mL was 
statistically significant (p < 0.05). In all three parameters, 
the first measurement was higher. The difference between 
the two measurements of creatinine, parathormone, 
MDRD, NGAL, FGF23, LVEDD, left atrium diameter and 
residual urine was not statistically significant in the initial 
evaluations of patients with proBNP >1000 pg/mL (p > 
0.05). 
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Table-2: Table 2: Comparison of patient group with proBNP <1000 pg/mL and >1000 pg/mL 
 
Patient group Pro-BNP >1000 pg/mL 
n = 10, (Mean±SD) 
Pro-BNP <1000 pg/mL 
n = 10, (Mean±SD) 
p-value 
Gender (female), n (%) 6 (60%) 5 (50%) 0.684 
Age (year) 44.7 ± 19.8 44.8 ± 11.7 0.684 
GFR (mL/min.) 12.7 ± 4.8 12.3 ± 6.4 0.739 
MDRD1 (mL/min.) 9.5 ± 4.2 7.5 ± 3.8 0.76 
Albumin (gr/dL) 3.1 ± 0.7 3.7 ± 0.3 0.023 
Calcium (mg/dL) 8.6 ± 0.6 9.0 ± 0.8 0.481 
Phosphorus (mg/dL) 5.5 ± 1.7 5.0 ± 1.6 0.529 
BMI (kg/m2) 22.9 ± 3.6 24.7 ± 5.6 0.393 
BUN1 (mg/dL) 52,9 ± 16,5 57,9 ± 25,3 0.971 
BUN2 (mg/dL) 42,3 ± 17,1 47,1 ± 8, 8 0.247 
Creatinine1 (mg/dL) 6,9 ± 2,8 8,0 ± 3,0 0.247 
Creatinine2 (mg/dL) 7,2 ± 2,9 7,1 ± 2,7 0.971 
PTH1 (pg/mL) 363,8 ± 278,1 374,8 ± 175,5 0.529 
PTH2 (pg/mL) 342,1 ± 334,6 266,8 ± 141,7 0.540 
proBNP1 (pg/mL) 13323,3 ± 11235,9 456,1 ± 266,7 0.000 
proBNP2 (pg/mL) 9667,3 ± 9483,2 1257,0 ± 2418,0 0.000 
NGAL1 (ng/mL) 178,9 ± 47,0 194,4 ± 56,5 0.481 
NGAL2 (ng/mL) 191,5 ± 53,7 228,3 ± 73,5 0.190 
FGF23.1 (pg/mL) 537,5 ± 733,9 374,3 ± 512,5 0.853 
FGF23.2 (pg/mL) 747,5 ± 1099,5 498,3 ± 821,9 0.739 
LVEDD 1 (cm) 4, 8 ± 0,7 4,4 ± 0,3 0.408 
LVEDD 2 (cm) 4.7 ± 0.7 4.6 ± 0.4 0.696 
Left atr d 1 (cm) 3.5 ± 0.7 3.2 ± 0.3 0.299 
Left atr d 2 (cm) 3.5 ± 0.7 3.5 ± 0.3 0.965 
Aortic root 1 (cm) 2.6 ± 0.4 2.9 ± 0.6 0.351 
Aortic root 2 (cm) 2.5 ± 0.4 2.5 ± 0.3 0.965 
Residual urine1 (mL/day) 805.0 ± 226.6 870.0 ± 249.7 0.481 
Residual urine 2 (mL/day) 835.0 ± 266.7 960,0 ± 275,7 0.353 
Δ proBNP (pg/mL) 6441.0 ± 8528.2 -800.9 ± 2245.4 0.001 
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Patient group Pro-BNP >1000 pg/mL 
n = 10, (Mean±SD) 
Pro-BNP <1000 pg/mL 
n = 10, (Mean±SD) 
p-value 
Gender (female), n (%) 6 (60%) 5 (50%) 0.684 
Age (year) 44.7 ± 19.8 44.8 ± 11.7 0.684 
GFR (mL/min.) 12.7 ± 4.8 12.3 ± 6.4 0.739 
MDRD1 (mL/min.) 9.5 ± 4.2 7.5 ± 3.8 0.76 
Δ NGAL (ng/mL) -12.6 ± 51.8 -33.8 ± 88.1 0.739 
Δ FGF23 (pg/mL) -20.9 ± 60.5 -4.8 ± 15.9 0.912 
Δ MDRD (mL/min.) 0.4 ± 1.4 -1.2 ± 3.8 0.315 
 
GFR: glomerular filtration rate; MDRD: Modification of Diet in Renal Disease; BMI: body mass index; BUN: blood urea 
nitrogen; PTH: parathormone; proBNP: N-terminal pro-brain natriuretic peptide; NGAL: neutrophil gelatinase-associated 
lipocalin; FGF23: fibroblast growth factor 23; LVEDD: left ventricular end-diastolic diameter; Left atr d: left atrium diameter; 
Aortic root: aortic root width; Residual urine: residual urine volume. The number 1 at the end of the units is added to indicate 
the first evaluation, and the second number is the second evaluation. Δ proBNP is the difference between the first and second 
evaluation of proBNP; Δ NGAL is the difference between the first and second evaluation of NGAL; Δ FGF23 is the difference 
between the first and second evaluation of FGF23; Δ MDRD is the difference between the first and second evaluation of 
MDRD.Accuracy comparisons within groups were demonstrated in table 3 and table 4. The highest marginal gap value was 
seen in proximal view of the group H (123.6±6.1 µm), and the highest internal gap value was detected in axial view of the 
same group (233.9±12.6 µm) (p<0.001). 
 
Table-3: Analysis of two separate measurements of first assessments of patients with proBNP < 1000 pg/mL 
 
Parameters Pro-BNP <1000 pg/mL 
n = 10, (Mean±SD) 
First Measurement 
Pro-BNP <1000 pg/mL 
n = 10, (Mean±SD) 
Second Measurement 
p-value 
BUN (mg/dL) 57.9 ± 25.3 47.1 ± 8.8 0.167 
Creatinine (mg/dL) 8.0 ± 3.0 7.1 ± 2.7 0.284 
PTH (pg/mL) 374.8 ± 175.5 266.8 ± 141.8 0.047 
MDRD (mL/min.) 7.5 ± 3.8 8.7 ± 4.5 0.424 
proBNP (pg/mL) 456.1 ± 266.7 1257.0 ± 2418.0 0.093 
NGAL (ng/mL) 194.4 ± 56.5 228.3 ± 73.5 0.646 
FGF23 (pg/mL) 374.3 ± 512.5 498.3 ± 821.9 0.114 
LVEDD (cm) 4.4 ± 0.3 4.6 ± 0.4 0.705 
Left atr d (cm) 3.2 ± 0.3 3.5 ± 0.3 0.136 
Aortic root (cm) 2.9 ± 0.6 2.5 ± 0.3 0.046 
Residual urine (mL/day) 870.0 ± 249.7 960.0 ± 275.7 0.041 
BUN: blood urea nitrogen; PTH: parathormone; MDRD: Modification of Diet in Renal Disease; proBNP: N-terminal pro-brain 
natriuretic peptide; NGAL: neutrophil gelatinase-associated lipocalin; FGF23: fibroblast growth factor 23; LVEDD: left 
ventricle end-diastolic diameter; Left atr d: left atrium diameter; Aortic root: aortic root width; Residual urine: residual urine 
volume. 
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On multivariate analysis, performed with the aim of 
determining serum NGAL level determinants, the albumin 
effect was found to be statistically significant (p <0.05). 
However, the difference between the first group of 
patients, age and proBNP was not statistically significant 
(p > 0.05) (Table 5). 
 
Table-4: Comparison of internal gap values within 
groups. 
 
Parameters Pro-BNP 
>1000 pg/mL 
n = 10, 
(Mean±SD) 
First 
Measurement 
Pro-BNP 
>1000 pg/mL 
n = 10, 
(Mean±SD) 
Second 
Measurement 
p- 
value 
BUN (mg/dL) 52.9 ± 16.5 42.3 ± 17.1 0.009 
Creatinine 
(mg/dL) 
6.9 ± 2.8 7.2 ± 2.9 0.540 
PTH (pg/mL) 363.8 ± 278.1 342.1 ± 334.6 0.739 
MDRD 
(mL/min.) 
9.5 ± 4.2 9.1 ± 4.3 0.395 
proBNP 
(pg/mL) 
13323.3 ± 
11235.9 
9667.3 ± 
9483.2 
0.035 
NGAL 
(ng/mL) 
178.9 ± 47.0 191.5 ± 53.7 0.333 
FGF23 
(pg/mL) 
537.5 ± 733.9 747.5 ± 1099.5 0.203 
LVEDD (cm) 4.8 ± 0.7 4.7 ± 0.7 0.414 
Left atr d (cm) 3.5 ± 0.7 3.5 ± 0.7 0.144 
Aortic root 
(cm) 
2.6 ± 0.4 2.5 ± 0.4 0.002 
Residual 
urine(mL/day) 
805.0 ± 0.4 835.0 ± 266.7 0.334 
 
BUN: blood urea nitrogen; PTH: parathormone; MDRD: 
Modification of Diet in Renal Disease; proBNP: N- 
terminal pro-brain natriuretic peptide; NGAL: neutrophil 
gelatinase-associated lipocalin; FGF23: fibroblast growth 
factor 23; LVEDD: left ventricle end-diastolic diameter; 
Left atr d: left atrium diameter; Aortic root: aortic root 
width; Residual urine: residual urine volume. 
Table 5: Factors affecting baseline serum NGAL level 
and of serum NGAL measured at the end of the 3rd 
month on multivariate analysis 
 
Parameter Variables R²: 0.245 
Depended 
variables 
Independent 
variables 
β p 
NGAL1 Albumin 0.495 0.026 
Patient group - 
0.143 
0.565 
Age 0.097 0.670 
NT-proBNP1 0.161 0.502 
NGAL2 Albumin 0.525 0.017 
Patient group 0.016 0.948 
Age 0.194 0.381 
Δ proBNP 0.203 0.371 
 
NGAL2: second evaluation of patients with neutrophil 
gelatinase-associated lipocalin; NT-proBNP1: first 
measurement of proBNP, Δ proBNP: difference between 
the first and second evaluations of proBNP. 
 
The effect of albumin on the second measurement of 
NGAL was statistically significant (p < 0.05). However, 
the difference between the first group of patients, age and 
proBNP was not statistically significant (p > 0.05). 
 
DISCUSSION 
 
In our study, the mean serum NT-proBNP level was 
6839.4±10168.4 pg/mL in the patient group, and  
46.7±23.0 pg/mL in control group. The mean serum 
NGAL level was 186.7±51.2 ng/mL in patients, while the 
control group had a mean of 83.1±29.1 ng/mL. The mean 
serum FGF23 level was 455±621.7 pg/mL in patients and 
20.8±16.7 in controls; serum NT-proBNP and NGAL 
levels of patients were significantly higher than in the 
control group (p <0.05). In patients with renal 
insufficiency, an increase in serum NT-proBNP and 
NGAL levels may be expected due to decreased clearance. 
 
According to established medical guidelines [16], the 
cut-off value to diagnose heart failure is 100 pg/mL (28.9 
pmol/L) for BNP and 300 pg/mL (35.4 pmol/L) for NT- 
proBNP, in patients with normal renal function. We 
preferred to use different cut-off values since there was a 
decrease in BNP or NT-proBNP clearances in  patients 
with impaired renal function. 
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Naganuma and colleagues reported an increased risk of 
cardiac death when plasma values were greater than 700 
pg/mL (200 pmol/L) in hemodialysis patients [17]. Wang 
et al found [18] that cardiovascular mortality and 
morbidity rates in peritoneal dialysis patients were the 
lowest when NT-pro-BNP levels were below 1928 pg/mL 
(227.5 pmol/L), and the highest when they were above 
17534 pg/mL (2069 pmol/L). In our study, we examined 
patients with NT-proBNP levels above and below 1000 
pg/mL. Mean serum NT-proBNP levels in the 
hypervolemic group, with serum NT-proBNP levels above 
1000 pg/mL, were found (13323.3 ± 11235.9 pg/mL). The 
mean serum NT-proBNP levels in the group with NT- 
proBNP levels below 1000 pg/mL were 456.1 ± 266.7 
pg/mL (p < 0.05) 
 
Damman et al. reported impairment in renal function 
and an increase in NGAL levels due to venous congestion 
in patients with right-sided heart failure. These 
investigators reported that NGAL in cardiac insufficiency 
is a good indicator of impairment of renal function [19]. 
Daniels et al found a relationship between NGAL and 
proBNP in a study of 1,393 Rancho Bernardo Study 
participants for an average of 11 years, and they found that 
NGAL is a strong indicator of death from cardiovascular 
disease and death due to all other causes [20]. They 
reported that this was independent of the change in GFR 
rate of the patients. NGAL could be used as an additional 
factor for other determinants such as NT-proBNP and C 
reactive protein for cardiovascular mortality. These 
investigators report that NGAL has a poor association with 
traditional cardiovascular risk factors such as age, systolic 
blood pressure, hypertension and diabetes. 
 
In this study of patients with residual renal function, 
we compared patients with severe hypervolemic peritoneal 
dialysis who had similar estimated GFR calculated by the 
Cockroft-Gault and Modification of Diet in Renal Disease 
study formulas and patients with peritoneal dialysis 
patients whose volume control was better with serum 
NGAL levels. There was no correlation between NGAL 
levels and LVEDD, left atrium diameter, aortic root width 
or residual urine volume. Similarly, Koca and colleagues 
found no association between NGAL levels and heart 
failure in their studies of hypertensive kidney function in 
normal patients with right-left heart failure [21]. 
 
In our study, we evaluated the serum NT-proBNP and 
NGAL levels after three months to assess changes in 
volume status of patients and their effect on serum NT- 
proBNP and NGAL levels. Serum NT-proBNP levels in 
patients with NT-proBNP levels >1000 pg/mL 
(hypervolemic group) and those with NT-proBNP levels 
<000 pg/mL (better volume control) at the first 
measurement compared to the initial measurements 
(13323.3±11235.9pg/ml) were significantly decreased (p 
<0.05). There was no significant change in NGAL levels. 
We found no significant change in serum NT-proBNP and 
NGAL levels in patients with better control of  volume 
with NT-proBNP levels <1000 pg/mL. There was no 
difference in the predicted GFR calculated by the 
Cockroft-Gault and MDRD study formulas between the 
two groups after three months of follow-up. 
 
In the multivariate regression analysis to determine the 
determinants of serum initial measurement of NGAL, we 
identified albumin as an independent determinant of 
NGAL when it was taken as a model group 1 
(hypervolemic group), age, serum albumin and NT- 
proBNP. In the multivariate regression analysis to 
determine the determinants of serum NGAL second 
measurement, we also found albumin as an independent 
predictor of NGAL when the change in age, serum 
albumin and serum NT-proBNP levels were taken as group 
1 (hypervolemic group). We saw that the other factors did 
not have an effect. 
 
The existence of NGAL on atherosclerotic plaques has 
been detected in studies. Vascular cells are most likely 
induced by the expression of NGAL during atherogenesis. 
However, the induction mechanism of NGAL in vascular 
cells is still unknown [22]. High FGF23 levels have been 
found to be associated with bone mineralization [23], pre 
dialysis progression in patients with CRF [24], LVH [25, 
26] and mortality in hemodialysis patients [27, 28]. In our 
study, we could not identify a relationship between NGAL 
and FGF23 levels. 
 
As a result, serum NT-proBNP and NGAL levels were 
significantly higher in the patient group than in the healthy 
control group. However, we could not detect a correlation 
between the levels of serum NT-proBNP and NGAL, 
which were evaluated as a sign of body volume status. 
Although our study is limited by the fact that it was 
performed on very few patients, it is important to note that 
other factors may have effects on serum NGAL. These 
include extracellular serum albumin in peritoneal dialysis 
patients and variables that we cannot fit into the 
multivariate analysis model. 
 
CONCLUSION 
 
The relation between serum NT-proBNP and NGAL levels 
and there are several other factors that may have effects on 
serum NGAL. This fact indicates the need for a more 
comprehensive study of hypervolemia and the reduction of 
NGAL and residual renal function, which is often 
encountered in patients with renal insufficiency. 
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